Meningococcal Group A，C Bivalent Polysaccharide Conjugate Vaccine(Walvax)

A、C群脑膜炎球菌多糖结合疫苗（沃森生物）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameMeningococcal Group A，C Bivalent Polysaccharide Conjugate Vaccine(Walvax)

Drug Alias NameA群C群脑膜炎球菌多糖结合疫苗Group A and Group C Meningococcal Conjugate Vaccine沃儿康

ClassificationVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Conjugated vaccineVaccines > National Immunization Program > Non-immunization program vaccine(Class II) +[4]

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsMeningitis, Meningococcal

Global Approved IndicationsMeningitis, Meningococcal

Approved Indications in ChinaMeningitis, Meningococcal

Original Approved Country/TerritoryMainland China

Original Approved Date2009/01/04

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusApproved

Highest Status in ChinaApproved

Originator CompaniesWalvax Biotechnology Co Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesYuxi Walvax Biotechnology Co Ltd

Inactive CompaniesN/A

Active IndicationsMeningitis, Meningococcal

Inactive IndicationsN/A

Other Information

ATC CodeJ07AH03